Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial

被引：0
|
作者：
Fizazi, K. [1 ]
Mella, P. Gonzalez
Castellano, D.
Minatta, J. N.
Kalebasty, A. R.
Shaffer, D.
Limon, J. C. Vazquez
Lopez, H. M. Sanchez
Armstrong, A. J.
Horvath, L.
Bastos, D. A.
Amin, N. P.
Li, J.
Unsal-Kacmaz, K.
Retz, M.
Saad, F.
Petrylak, D. P.
Pachynski, R. K.
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
D O I：
10.1097/JU.0000000000003046
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：445 / 446
页数：2
相关论文
共 50 条
  • [31] Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naive Castration-resistant Prostate Cancer: Final Results of a Phase II Trial
    Nabhan, Chadi
    Lestingi, Timothy M.
    Galvez, Angel
    Tolzien, Kathy
    Kelby, Susan K.
    Tsarwhas, Dean
    Newman, Steven
    Bitran, Jacob D.
    UROLOGY, 2009, 74 (03) : 665 - 671
  • [32] The PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
    Kim, Choung-Soo
    Theeuwes, Ad
    Kwon, Dong Deuk
    Choi, Young Deuk
    Chung, Byung Ha
    Lee, Hyun Moo
    Lee, Kang Hyun
    Lee, Sang Eun
    INVESTIGATIVE AND CLINICAL UROLOGY, 2016, 57 (03) : 174 - 183
  • [33] Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
    Pu, Yeong-Shiau
    Ahn, Hanjong
    Han, Weiqing
    Huang, Shu-Pin
    Wu, Hsi-Chin
    Ma, Lulin
    Yamada, Shunsuke
    Suga, Kazutaka
    Xie, Li-Ping
    ADVANCES IN THERAPY, 2022, 39 (06) : 2641 - 2656
  • [34] A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
    Chi, Kim N.
    Hotte, Sebastien J.
    Ellard, Susan
    Gingerich, Joel Roger
    Joshua, Anthony Michael
    Kollmannsberger, Christian K.
    Yu, Evan Y.
    Gleave, Martin Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [35] Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
    Dong, Baijun
    Fan, Liancheng
    Wang, Yanqing
    Chi, Chenfei
    Ma, Xiaowei
    Wang, Rui
    Cai, Wen
    Shao, Xiaoguang
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Xin, Zhixiang
    Hu, Jianian
    Xie, Shaowei
    Kang, Xiaonan
    Zhou, Lixin
    Xue, Wei
    PROSTATE, 2017, 77 (13): : 1373 - 1380
  • [36] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
    Dhawan, Mallika Sachdev
    Lee, Mina
    Bryce, Alan H.
    Weinberg, Vivian K.
    Ryan, Charles J.
    Derleth, Christina Louise
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [38] COST-EFFECTIVENESS ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN
    Okumura, H.
    Inoue, S.
    Naidoo, S.
    Holmstrom, S.
    Akaza, H.
    VALUE IN HEALTH, 2017, 20 (05) : A107 - A107
  • [39] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Buonerba, Carlo
    Federico, Piera
    D'Aniello, Carmine
    Rescigno, Pasquale
    Cavaliere, Carla
    Puglia, Livio
    Ferro, Matteo
    Altieri, Vincenzo
    Perdona, Sisto
    De Placido, Sabino
    Lorenzo, Giuseppe Di
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1455 - 1461
  • [40] Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2019, 15 (02): : 86 - 99
12345